» Articles » PMID: 23846621

Platelets Are a Previously Unrecognised Source of MIF

Overview
Journal Thromb Haemost
Publisher Thieme
Date 2013 Jul 13
PMID 23846621
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine with chemokine-like functions and a role in atherogenesis. MIF is secreted by various cells including endothelial cells and macrophages. Platelets are another prominent cell type with a role in atherogenesis and are a rich source of atherogenic chemokines. We asked whether platelets express and secrete MIF. In comparison, CXCL12 release was determined. We examined the subcellular localisation of MIF in platelets/megakaryocytes, studied its co-localisation with other platelet-derived mediators and asked whether platelets contain MIF mRNA. Moreover, we probed the functional role of platelet-derived MIF in inflammatory cell recruitment. Using Western blot and ELISA, we demonstrated and quantitated MIF protein in human and mouse platelets. Applying confocal-microscopy, MIF was found to localise in granular-like structures, but did not co-localise with known platelet cytokines. qPCR indicated that platelets contain low levels of MIF mRNA. ELISA measurements from human platelet supernatants showed that, whereas thrombin and collagen triggered the release of MIF and CXCL12, ADP and oxidised LDL promoted CXCL12 but not MIF secretion. Using Transwell assays, we demonstrated that platelet supernatants promoted monocyte chemotaxis and that this was blocked by neutralising MIF antibodies.This is the first report demonstrating MIF secretion from activated platelets, suggesting that platelets are a previously unrecognised source of MIF in inflammatory processes. There are distinct activating stimuli for MIF and CXCL12 secretion. A substantial portion of the chemotactic capacity of stimulated platelet supernatants is contributed by MIF, suggesting a role for platelet-derived MIF in atherogenic cell recruitment.

Citing Articles

An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.

El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E Nat Commun. 2025; 16(1):2297.

PMID: 40055309 PMC: 11889166. DOI: 10.1038/s41467-025-57540-z.


Macrophage migration inhibitory factor levels are associated with disease activity and possible complications in membranous nephropathy.

Ding N, Li P, Wu K, Lv T, Yu W, Hao J Sci Rep. 2022; 12(1):18558.

PMID: 36329091 PMC: 9633699. DOI: 10.1038/s41598-022-23440-1.


Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation.

Brandhofer M, Hoffmann A, Blanchet X, Siminkovitch E, Rohlfing A, El Bounkari O Cell Mol Life Sci. 2022; 79(10):512.

PMID: 36094626 PMC: 9468113. DOI: 10.1007/s00018-022-04539-0.


Oxidised Low-Density Lipoprotein-Induced Platelet Hyperactivity-Receptors and Signalling Mechanisms.

Berger M, Naseem K Int J Mol Sci. 2022; 23(16).

PMID: 36012465 PMC: 9409144. DOI: 10.3390/ijms23169199.


Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology.

Chatterjee M Cells. 2022; 11(2).

PMID: 35053329 PMC: 8773869. DOI: 10.3390/cells11020213.